Melanoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Melanoma originates from melanocytes found in pigmented tissues, including the skin, eyes, and intestines. Approximately 90% of melanoma cases are initially diagnosed as primary tumors, showing no signs of metastasis. However, melanoma tends to spread to the brain when it becomes malignant. The major oncogenic mutations associated with melanoma involve genes like BRAF, NRAS, c-KIT, PTEN, and GNAQ/GNA11. Among these, BRAF mutations are the most extensively studied, with a prevalence ranging from 50% to 60% in primary melanoma cases. A small percentage, around 5% to 12% of melanoma patients, have a family history of cutaneous malignant melanoma (CMM) in their first-degree relatives. Over 75 somatic mutations in the BRAF gene have been identified in melanoma, all of which lead to the constitutive activation of BRAF. These mutations are found in the activating segment within exon 15 or the glycine-rich loop (P-loop) in exon 11 of the BRAF protein's kinase domain. In BRAF mutant melanoma cases, V600E mutations account for 74% to 90%, while V600K mutations make up 16% to 29% of the cases. The frequency of BRAF mutations in primary melanomas varies from 50% to 60%.

·       In the United States, the estimated incidence of melanoma is approximately 25.3 cases per 100,000 people.

 

Thelansis’s “Melanoma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Melanoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Melanoma across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Melanoma Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Melanoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Melanoma, Melanoma market outlook, Melanoma competitive landscape, Melanoma market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)